Spectral Molecular Imaging Inc. (SMI) said it recently completed development of its initial product, SkinSpect, aimed at early detection of melanoma through its proprietary form of hyperspectral imaging. Unveiled on Sept. 29, 2010, at its headquarters to colleagues, medical professionals and device experts, SkinSpect incorporates advances in hyperspectral imaging, autofluorescence measurement and polarization-gated detection, according to Dr. Erik Lindsley, president of SMI. Its software controlling image acquisition and handling is new, and it is driven by an intuitive touchscreen interface to allow for effortless data and patient monitoring, image archiving and analysis, and Internet-based data transfer and tele-consults. In addition, its design is compliant with electronic medical record generation and tracking. “The new system is extremely versatile in acquiring high-resolution image data noninvasively from suspicious skin lesions, on the surface and under it, with a speed that minimizes motion artifacts,” said Dr. Daniel Farkas, chairman and CEO. SMI is a development-stage, medical imaging device company that applies its proprietary hyperspectral-optical imaging technology to advance the early and accurate diagnoses of cancer and precancerous conditions. It is a wholly-owned subsidiary of Cascade Technologies Corp. For more information, visit: www.spectralmi.com